IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C

Table 1 Characteristics of patients

IL28B polymorphism	n (%)	SVR (%)	Gender (M/F)	Age (yr)	BMI(kg/m2)
CC	13 (20)	77
CT	34 (53)	38
TT	17 (27)	6
All	64	39	27/37	44 ± 12	27 ± 5

The values of BMI and age given as arithmetic mean and standard deviation. CC, CT and TT: Single nucleotide polymorphisms at location rs12979860 IL28B; SVR: Sustained virological response; BMI: Body mass index; M/F: Male/female.

Table 2 Odds ratios of sustained virological response, depending on type of polymorphism of IL28B, inflammation activity, fibrosis, fatty liver, baseline hepatitis C virus viral load, the level of platelets and insulin resistance

Features affecting SVR	P value	OR	95% CI
CC vs TT	< 0.001	25	3.5-177.5
Platelets CT	0.002	12.8	1.8-42.6
Staging	0.008	5.9	1.5-23.8
CC vs CT	0.018	5.4	1.2 -23.3
Fatty liver	0.014	4.8	1.2-13.6
Platelets	0.005	4.7	1.3-17.3
Grading	0.026	3.9	1.1-13.4
Insulin resistance	0.029	3.9	1.1-13.8
HCV viremia	0.038	3	1-8.8

Difference in the risk of a SVR between patients with the CC allele and TT and CT alleles, low and high activity of the inflammatory process (G < 1 vs G > 1, according to METAVIR), little and advanced fibrosis (F < 1 vs F > 1, according to METAVIR), low and high hepatitis C viral load (< 10⁶ IU/mL vs > 10⁶ IU/mL), and absence or presence of fatty liver, high and low platelet count (> 200 × 10⁹/L vs < 200 × 10⁹/L), low or high insulin resistance index (< 2.5 vs > 2.5). Platelets CT: OR of SVR in patients with genotype CT with normal vs low platelets. SVR: Sustained virological response; CI: Confidence interval; HCV: Hepatitis C virus; OR: Odds ratio.